37-year-old female patient (

BMI 20.7) with a right adrenal gland tumor (10 cm)

. She had symptoms of Conn’s syndrome (hypokalemia, hypertension)

. No distant metastases were found in preoperative imaging


.

The patient was scheduled for laparoscopic right adrenalectomy.

The video shows the full procedure (2x speed).

Velvet Lamb was diagnosed in 2015 with stage 4 adrenal cortical carcinoma. A one in a million diagnosis with a poor prognosis, listen to Velvet's story of hope.
#adrenalcancer #acc #neuroendocrinecancer #columbiauniversity #medicalconference #nih #neuroendocrinecancer #neuroendocrinetumor #cancersurvivor #moffittcancercenter #universityofcolorado

Matthew Campbell, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on an Phase II study (NCT03370718) exploring the role of carbozantinib, a tyrosine kinase inhibitor, in adrenocortical carcinoma (ACC) management. 18 patients were enrolled with advanced ACC, with the primary endpoint being progression-free survival (PFS) at 4 months (PFS4). The median follow-up was 19.4 months and the PFS4 was 72%, median PFS was 7.2 months. 16 patients had restaging with ORR including 2 partial response, 12 stable disease, and 2 progressive disease as best response; disease control rate was 78%. The median PFS was 7.2 months and median OS was 23.9 months. Overall, cabozantinib was shown to be able to provide sustained disease control in patients with advanced ACC and a manageable safety profile in the majority of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.